Biosafety

About: Biosafety is a research topic. Over the lifetime, 2095 publications have been published within this topic receiving 19378 citations.

Biosafety in microbiological and biomedical laboratories

Abstract: African horse sickness (AHSV) 246, 350, 353-55, 373, 401 African swine fever virus (ASFV) 246, 350, 352, 373, 401 Agriculture Agents 343, 352 Agriculture pathogen biosafety 343 Akabane virus 350, 354, 401 Allergic reactions 192 animal biosafety levels 61 Animal Biosafety Levels (ABSL) 60 Animal Biosafety Level 1 61 Animal Biosafety Level 2 67 Animal Biosafety Level 3 61, 75 Animal Biosafety Level 4 85 Animal facilities 27, 60, 91, 173, 243, 361-63, 372 Anthrax iii, 104, 123-24, 161, 273 Arboviruses 2, 5, 233, 236, 238-40, 246, 265-267 arenaviruses 234, 237 armadillos 144-45, 166 Arthropod containment 61, 160, 169, 377-78, 401 Ascaris 192-93

Gene Therapy Progress and Prospects: Development of improved lentiviral and retroviral vectors – design, biosafety, and production

Abstract: Replication defective vectors derived from simple retroviruses or the more complex genomes of lentiviruses continue to offer the advantages of long-term expression, cell and tissue specific tropism, and large packaging capacity for the delivery of therapeutic genes. The occurrence of adverse events caused by insertional mutagenesis in three patients in a gene therapy trial for X-linked SCID emphasizes the potential for problems in translating this approach to the clinic. Several genome-wide studies of retroviral integration are now providing novel insights into the integration site preferences of different vector classes. We review recent developments in vector design, integration, biosafety, and production.

Laboratory-associated infections and biosafety.

Abstract: An estimated 500,000 laboratory workers in the United States are at risk of exposure to infectious agents that cause disease ranging from inapparent to life-threatening infections, but the precise risk to a given worker unknown. The emergence of human immunodeficiency virus and hantavirus, the continuing problem of hepatitis B virus, and the reemergence of Mycobacterium tuberculosis have renewed interest in biosafety for the employees of laboratories and health care facilities. This review examines the history, the causes, and the methods for prevention of laboratory-associated infections. The initial step in a biosafety program is the assessment of risk to the employee. Risk assessment guidelines include the pathogenicity of the infectious agent, the method of transmission, worker-related risk factors, the source and route of infection, and the design of the laboratory facility. Strategies for the prevention and management of laboratory-associated infections are based on the containment of the infectious agent by physical separation from the laboratory worker and the environment, employee education about the occupational risks, and availability of an employee health program. Adherence to the biosafety guidelines mandated or proposed by various governmental and accrediting agencies reduces the risk of an occupational exposure to infectious agents handled in the workplace.